PAFAH1B3 and non-small cell lung carcinoma: Finally, high expression of PAFAH1B3 correlated with poor overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in non-small cell lung cancer (NSCLC) and liver hepatocellular carcinoma (LIHC), and has the potential as an independent risk factor for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in liver hepatocellular carcinoma (LIHC).